世界最新医学信息文摘（连续型电子期刊）
世界最新醫學信息文摘（連續型電子期刊）
세계최신의학신식문적（련속형전자기간）
World Latest Medicine Information
2014年
35期
18-18,20
,共2页
精神分裂症%丙戊酸镁%攻击行为%联合用药
精神分裂癥%丙戊痠鎂%攻擊行為%聯閤用藥
정신분렬증%병무산미%공격행위%연합용약
schizophrenia%Magnesium valproate%aggression%combining therapy
目的：探究丙戊酸镁联合抗精神病药物对精神分裂症攻击行为的治疗效果。方法收集我院具有精神分裂症攻击行为的患者150例，将所有患者分为：a组利培酮+丙戊酸镁组（58例）；b组喹硫平+丙戊酸镁组（48例）；c组利培酮组（44例），只给予利培酮治疗。a组和b组都在治疗的同时联合丙戊酸镁（400～600mg/日）。在治疗前、治疗2周末和治疗4周末使用阳性与阴性症状量表（panss）评定疗效、用外显攻击行为量表（moas）（修订版）评定患者的攻击行为、用不良反应量表（tess）评定患者发生的不良反应。结果三组治疗后panss评分都比治疗前明显降低（P＜0.01），在治疗2周末，a组panss评分较b组、c组差异有显著性（P＜0.01）；而在治疗4周末，三个组比较无差异（P＞0.05）；三组治疗后moas评分都比治疗前明显降低（P＜0.01）；而在治疗4周后，三组比较差异有显著性（P＜0.01）；在治疗2周后b组与a组、c组相比较具有显著性差异P＜0.01）；tess评分在治疗4周末，a组、b组与c组比较有显著性差异（P＜0.01）；其中b组与a组相比也有显著性差异（P＜0.01）。结论抗精神病药物联合小剂量的丙戊酸镁治疗精神分裂症攻击行为疗效显著，且治疗过程中不良反应少。
目的：探究丙戊痠鎂聯閤抗精神病藥物對精神分裂癥攻擊行為的治療效果。方法收集我院具有精神分裂癥攻擊行為的患者150例，將所有患者分為：a組利培酮+丙戊痠鎂組（58例）；b組喹硫平+丙戊痠鎂組（48例）；c組利培酮組（44例），隻給予利培酮治療。a組和b組都在治療的同時聯閤丙戊痠鎂（400～600mg/日）。在治療前、治療2週末和治療4週末使用暘性與陰性癥狀量錶（panss）評定療效、用外顯攻擊行為量錶（moas）（脩訂版）評定患者的攻擊行為、用不良反應量錶（tess）評定患者髮生的不良反應。結果三組治療後panss評分都比治療前明顯降低（P＜0.01），在治療2週末，a組panss評分較b組、c組差異有顯著性（P＜0.01）；而在治療4週末，三箇組比較無差異（P＞0.05）；三組治療後moas評分都比治療前明顯降低（P＜0.01）；而在治療4週後，三組比較差異有顯著性（P＜0.01）；在治療2週後b組與a組、c組相比較具有顯著性差異P＜0.01）；tess評分在治療4週末，a組、b組與c組比較有顯著性差異（P＜0.01）；其中b組與a組相比也有顯著性差異（P＜0.01）。結論抗精神病藥物聯閤小劑量的丙戊痠鎂治療精神分裂癥攻擊行為療效顯著，且治療過程中不良反應少。
목적：탐구병무산미연합항정신병약물대정신분렬증공격행위적치료효과。방법수집아원구유정신분렬증공격행위적환자150례，장소유환자분위：a조리배동+병무산미조（58례）；b조규류평+병무산미조（48례）；c조리배동조（44례），지급여리배동치료。a조화b조도재치료적동시연합병무산미（400～600mg/일）。재치료전、치료2주말화치료4주말사용양성여음성증상량표（panss）평정료효、용외현공격행위량표（moas）（수정판）평정환자적공격행위、용불량반응량표（tess）평정환자발생적불량반응。결과삼조치료후panss평분도비치료전명현강저（P＜0.01），재치료2주말，a조panss평분교b조、c조차이유현저성（P＜0.01）；이재치료4주말，삼개조비교무차이（P＞0.05）；삼조치료후moas평분도비치료전명현강저（P＜0.01）；이재치료4주후，삼조비교차이유현저성（P＜0.01）；재치료2주후b조여a조、c조상비교구유현저성차이P＜0.01）；tess평분재치료4주말，a조、b조여c조비교유현저성차이（P＜0.01）；기중b조여a조상비야유현저성차이（P＜0.01）。결론항정신병약물연합소제량적병무산미치료정신분렬증공격행위료효현저，차치료과정중불량반응소。
Objective research of magnesium valproate combined with antipsychotic drugs on aggressive behavior in patients with schizophrenia treatment effect. Methods 150 patients were collected in our hospitalwith aggressive behavior in patients with schizophrenia, all patients were divided into a groups:risperidone+magnesium valproate group (58 cases);b group of quetiapine+magnesium valproate group (48 cases);group c (44 cases), risperidone risperidone therapy only. a group and b group at the same time of treatment combined with magnesium valproate (400 to 600mg/d).Before treatment, 2 weeks treatment and 4 weekend using the positive and negative symptom scale (panss) for evaluating the curative effect and overt aggression scale (moas) (revised edition) attack behavior, evaluation of patients with adverse reactions scale (tess) assessmentof patients with adverse reactions occur. Results Of the three groups after treatment panss score were signiifcantly lower than those before treatment (P<0.01), in the treatment of 2 over the weekend, a group compared with b group, the panss score in group c was signiifcantdifference (P<0.01);and in the 4 weeks treatment, no difference to compare three groups (P>0.05);the three group after treatment, moas score were signiifcantly lower than those before treatment (P<0.01);and in the 4 weeks after treatment, there were signiifcant difference between three groups (P<0.01);in 2 weeks after the treatment, b group and a group and c group compared with a signiifcant difference in P<0.01);the tess score in the treatment of 4 over the weekend, a group and b group compared with c group have signiifcant difference (P<0.01);in the b group compared with a group also had signiifcant difference (P< 0.01). Conclusions effect ofmagnesium valproate in the treatment of mental conclusion antipsychotics combined with smalldose of disease attack behavior splitting signiifcantly, and less adverse reaction duringtreatment.
